...home of the St. Johns Medical College Community

  • Increase font size
  • Default font size
  • Decrease font size
Home What's New NA Chapter Dr O'Neill Dcruz appointed as Chief Medical Officer Cyberonics

Dr O'Neill Dcruz appointed as Chief Medical Officer Cyberonics

E-mail Print PDF

O'Neill D'Cruz

Cyberonics (Nasdaq: CYBX), a Houston-based medical technology company, has hired Dr. O'Neill D'cruz as chief medical officer.D'Cruz comes to Cyberonics from UCB S.A., a multinational biopharmaceutical manufacturing company headquartered in Belgium, where he served as medical director of neurobiology.

Dr. D'Cruz was most recently Medical Director, Neurology at UCB, S.A., and previously Professor of Neurology and Pediatrics at University of North Carolina-Chapel Hill.  He also earned a Master of Business Administration at the Kenan-Flagler Business School, UNC-Chapel Hill.  In addition to industry experience in clinical development, pharmacovigilance, regulatory interactions, public-private partnerships and business development, Dr. D'Cruz has worked in the field of epilepsy for over two decades, as a board-certified neurologist and epileptologist, health policy and patient advocate, clinical investigator and consultant to leading pharmaceutical companies.  Dr. D'Cruz was an investigator in Cyberonics' E-05 study, the pivotal study used to obtain the company's original PMA approval for the VNS Therapy® System in 1997, as well as in clinical studies of most of the currently-marketed second-generation anti-epileptic drugs.He is an alumnus from batch 1978.

"We have made significant, multi-year investments in our sales force capabilities and our technology pipeline," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "The AspireSR™ pulse generator, with seizure detection and response technology, recently received CE-mark approval in Europe, and the Centro™ and ProGuardian™ products are nearing regulatory submissions.  With Rohan as COO for the Epilepsy business and Neil as CMO, we have restructured the team and added new personnel to better focus our efforts on epilepsy market-development activities."


blog comments powered by Disqus